Resveratrol Confers Protection against Rotenone-Induced Neurotoxicity by Modulating Myeloperoxidase Levels in Glial Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chang, Chi Young ^a,b   Choi, Dong Kug ^c   Lee, Dae Kee ^b   Hong, Young Jun ^d   Park, Eun Jung ^a  

^a National Cancer Center   (South Korea)

^b Ewha Womans University   (South Korea)

^c Konkuk University   (South Korea)

^d Korea Cancer Center Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROTENONE;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; COCULTURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; EMBRYO; GLIA CELL; MICROGLIA; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PHAGOCYTOSIS; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ASTROCYTES; DOWN-REGULATION; FEMALE; MICROGLIA; NEUROGLIA; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRIC OXIDE; PEROXIDASE; PREGNANCY; RATS, SPRAGUE-DAWLEY; ROTENONE; STILBENES;

MUS;

EID: 84875970786     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060654     Document Type: Article

References (50)

1. Klebanoff SJ, (2005) Myeloperoxidase: friend and foe. J Leukoc Biol 77: 598-625.
2. Davies MJ, (2011) Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention. J Clin Biochem Nutr 48: 8-19.
3. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, et al. (2002) Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277: 46116-46122.
4. Matthijsen RA, Huugen D, Hoebers NT, de Vries B, Peutz-Kootstra CJ, et al. (2007) Myeloperoxidase is critically involved in the induction of organ damage after renal ischemia reperfusion. Am J Pathol 171: 1743-1752.
5. McMillen TS, Heinecke JW, LeBoeuf RC, (2005) Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111: 2798-2804.
6. Sawayama Y, Miyazaki Y, Ando K, Horio K, Tsutsumi C, et al. (2008) Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein. Leukemia 22: 956-964.
7. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, et al. (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 25: 6594-6600.
8. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, et al. (2001) Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107: 419-430.
9. Milla C, Yang S, Cornfield DN, Brennan ML, Hazen SL, et al. (2004) Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol 287: L706-714.
10. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, et al. (2000) Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 104: 10-15.
11. Chang CY, Song MJ, Jeon SB, Yoon HJ, Lee DK, et al. (2011) Dual functionality of myeloperoxidase in rotenone-exposed brain-resident immune cells. Am J Pathol 179: 964-979.
12. Delmas D, Jannin B, Latruffe N, (2005) Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res 49: 377-395.
13. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
14. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6: e19881.
15. de la Lastra CA, Villegas I, (2005) Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 49: 405-430.
16. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, et al. (2010) Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 78: 466-477.
17. Macmillan-Crow LA, Cruthirds DL, (2001) Invited review: manganese superoxide dismutase in disease. Free Radic Res 34: 325-336.
18. Robb EL, Page MM, Wiens BE, Stuart JA, (2008) Molecular mechanisms of oxidative stress resistance induced by resveratrol: Specific and progressive induction of MnSOD. Biochem Biophys Res Commun 367: 406-412.
19. Pasinetti GM, Wang J, Marambaud P, Ferruzzi M, Gregor P, et al. (2011) Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp Neurol 232: 1-6.
20. Bournival J, Quessy P, Martinoli MG, (2009) Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 29: 1169-1180.
21. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, et al. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54: 111-118.
22. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, et al. (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23: 10756-10764.
23. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, et al. (2011) Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119: 866-872.
24. Gao HM, Hong JS, Zhang W, Liu B, (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 23: 1228-1236.
25. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
26. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, et al. (2002) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296: 2391-2394.
27. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, et al. (1998) Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391: 393-397.
28. Jou I, Lee JH, Park SY, Yoon HJ, Joe EH, et al. (2006) Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am J Pathol 168: 1619-1630.
29. Han BS, Hong HS, Choi WS, Markelonis GJ, Oh TH, et al. (2003) Caspase-dependent and-independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci 23: 5069-5078.
30. Gao HM, Liu B, Hong JS, (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23: 6181-6187.
31. Yang MS, Park EJ, Sohn S, Kwon HJ, Shin WH, et al. (2002) Interleukin-13 and-4 induce death of activated microglia. Glia 38: 273-280.
32. Collo G, Zanetti S, Missale C, Spano P, (2008) Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci 28: 1231-1240.
33. Lu X, Ma L, Ruan L, Kong Y, Mou H, et al. (2010) Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 7: 46.
34. Neumann H, Kotter MR, Franklin RJ, (2009) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132: 288-295.
35. Caron E, Hall A, (1998) Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282: 1717-1721.
36. Dohi K, Ohtaki H, Nakamachi T, Yofu S, Satoh K, et al. (2010) Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury. J Neuroinflammation 7: 41.
37. Miller RL, James-Kracke M, Sun GY, Sun AY, (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34: 55-65.
38. Moore DJ, West AB, Dawson VL, Dawson TM, (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
39. Radad K, Rausch WD, Gille G, (2006) Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int 49: 379-386.
40. Drolet RE, Cannon JR, Montero L, Greenamyre JT, (2009) Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 36: 96-102.
41. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, et al. (2010) Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5: e8762.
42. Alam M, Schmidt WJ, (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136: 317-324.
43. Bianchini F, Vainio H, (2003) Wine and resveratrol: mechanisms of cancer prevention? Eur J Cancer Prev 12: 417-425.
44. Kumar AP, Ryan C, Cordy V, Reynolds WF, (2005) Inducible nitric oxide synthase expression is inhibited by myeloperoxidase. Nitric Oxide 13: 42-53.
45. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, et al. (2005) Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci U S A 102: 431-436.
46. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, et al. (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285: 9100-9113.
47. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, et al. (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-447.
48. Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, et al. (2007) Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4: 25.
49. Perry VH, Nicoll JA, Holmes C, (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201.
50. Sherer TB, Betarbet R, Kim JH, Greenamyre JT, (2003) Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341: 87-90.